147 related articles for article (PubMed ID: 38393945)
41. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.
Gibiansky L; Frey N
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):5-16. PubMed ID: 22101760
[TBL] [Abstract][Full Text] [Related]
42. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling.
Li H; Wang H; Nicholas J
J Virol; 2001 Apr; 75(7):3325-34. PubMed ID: 11238858
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
44. Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis.
Maioli G; Caporali R; Favalli EG
Expert Opin Drug Discov; 2022 Aug; 17(8):799-813. PubMed ID: 35757853
[TBL] [Abstract][Full Text] [Related]
45. The amino acid exchange R28E in ciliary neurotrophic factor (CNTF) abrogates interleukin-6 receptor-dependent but retains CNTF receptor-dependent signaling via glycoprotein 130 (gp130)/leukemia inhibitory factor receptor (LIFR).
Wagener EM; Aurich M; Aparicio-Siegmund S; Floss DM; Garbers C; Breusing K; Rabe B; Schwanbeck R; Grötzinger J; Rose-John S; Scheller J
J Biol Chem; 2014 Jun; 289(26):18442-50. PubMed ID: 24802752
[TBL] [Abstract][Full Text] [Related]
46. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
[TBL] [Abstract][Full Text] [Related]
47. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
48. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.
Chen F; Teachey DT; Pequignot E; Frey N; Porter D; Maude SL; Grupp SA; June CH; Melenhorst JJ; Lacey SF
J Immunol Methods; 2016 Jul; 434():1-8. PubMed ID: 27049586
[TBL] [Abstract][Full Text] [Related]
49. Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production.
Igaz P; Horváth A; Horváth B; Szalai C; Pállinger E; Rajnavölgyi E; Tóth S; Rose-John S; Falus A
Immunol Lett; 2000 Mar; 71(3):143-8. PubMed ID: 10722865
[TBL] [Abstract][Full Text] [Related]
50. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Zhang C; Wu Z; Li JW; Zhao H; Wang GQ
Int J Antimicrob Agents; 2020 May; 55(5):105954. PubMed ID: 32234467
[TBL] [Abstract][Full Text] [Related]
51. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
52. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H
Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180
[TBL] [Abstract][Full Text] [Related]
53. Discovery of IL-6 and Development of Anti-IL-6R Antibody.
Kishimoto T
Keio J Med; 2019; 68(4):96. PubMed ID: 31875623
[TBL] [Abstract][Full Text] [Related]
54. Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation.
Pflanz S; Kurth I; Grötzinger J; Heinrich PC; Müller-Newen G
J Immunol; 2000 Dec; 165(12):7042-9. PubMed ID: 11120832
[TBL] [Abstract][Full Text] [Related]
55. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers.
Rose-John S; Schooltink H
Recent Results Cancer Res; 2007; 174():57-66. PubMed ID: 17302185
[TBL] [Abstract][Full Text] [Related]
56. Interleukin-6 and its receptor: from bench to bedside.
Scheller J; Rose-John S
Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
[TBL] [Abstract][Full Text] [Related]
57. Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts.
Vermes C; Jacobs JJ; Zhang J; Firneisz G; Roebuck KA; Glant TT
J Biol Chem; 2002 May; 277(19):16879-87. PubMed ID: 11884403
[TBL] [Abstract][Full Text] [Related]
58. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
[TBL] [Abstract][Full Text] [Related]
59. sIL-6R: more than an agonist?
Knüpfer H; Preiss R
Immunol Cell Biol; 2008 Jan; 86(1):87-91. PubMed ID: 17724457
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
